Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine dosing in post-PCI coronary heart disease
NCT06078904Phase 4Completed
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of colchicine in coronary artery disease (CAD) (4 arms). Primary endpoint: High-sensitivity C-reactive Protein at 4 weeks. Started Oct 2023; status: completed.
02
Drugs
colchicine
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06078904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06078904.